HomeBUSINESS
BUSINESS

Will Pricing Reform Spur Divestment of Off-Patent Brands in Japan? Next 3 Months Hold Key for Future Directions
(Jan.1.2018)

By Reiji Anasako

With a major pricing overhaul looming in April, drug makers in Japan are being urged to retool their business models and FY2018 budgets so as to adapt themselves to the anticipated changes. The past two years have seen active deal-making in the off-patent drug arena, and the market is now questioning whether a complex new pricing scheme for long-listed products (LLPs), or off-patent brands with generic equivalents, will further accelerate this move, or not ...
(LOG IN FOR FULL STORY)

News Calendar